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Abstract
Pre-mRNA splicing is an essential step in the process 
of gene expression in eukaryotes and consists of the 
removal of introns and the linking of exons to generate 
mature mRNAs. This is a highly regulated mechanism 
that allows the alternative usage of exons, the retention 
of intronic sequences and the generation of exonic se-
quences of variable length. Most human genes undergo 
splicing events, and disruptions of this process have 
been associated with a variety of diseases, including 
cancer. Hepatocellular carcinoma (HCC) is a molecularly 
heterogeneous type of tumor that usually develops in a 
cirrhotic liver. Alterations in pre-mRNA splicing of some 
genes have been observed in liver cancer, and although 
still scarce, the available data suggest that splicing de-
fects may have a role in hepatocarcinogenesis. Here 
we briefly review the general mechanisms that regulate 
pre-mRNA splicing, and discuss some examples that 
illustrate how this process is impaired in liver tumori-
genesis, and may contribute to HCC development. We 
believe that a more thorough examination of pre-mRNA 
splicing is still needed to accurately draw the molecular 
portrait of liver cancer. This will surely contribute to a 
better understanding of the disease and to the develop-
ment of new effective therapies.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is a deadly disease, and 
is currently ranked as the fifth most common cancer 
worldwide[1]. Most cases of  HCC emerge on a back-
ground of  chronic liver injury and inflammation induced 
by viral infection (hepatitis B and C viruses), chronic 
alcohol abuse, exposure to hepatotoxins (such as afla-
toxin B), and genetic or metabolic conditions (such as 
haemochromatosis, 1-antitrypsin deficiency, obesity or 
diabetes)[2]. The end-stage of  chronic liver disease is liver 
cirrhosis, characterised at the histological level by the mas-
sive deposition of  extracellular matrix in fibrous septa 
that surround regenerative nodules. In these regenerative 
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nodules, partially dedifferentiated hepatocytes are driven 
by a pro-inflammatory milieu to divide in an attempt to 
restore the lost functional mass, frequently giving rise to 
foci of  dysplastic cells[3,4]. Accumulating evidence indicates 
that this microenvironment favours the development of  
mutations and genetic alterations that are at the origin of  
the malignant transformation of  the liver[5-7]. In view of  
this, chronic hepatitis and cirrhosis are considered as pre-
neoplastic conditions. Nevertheless, a small but sizeable 
proportion of  HCCs develop in normal liver tissues, in 
the absence of  any known risk factor for liver cancer. The 
mechanisms leading to cancer in this small but sizeable 
minority of  HCC cases are not known[1].
HCCs are complex tumors from the molecular point 
of  view[8,9]. Over the past decade many efforts have been 
made to identify the molecular alterations that take place 
during the development of  HCC. High throughput array-
based techniques evaluating gene expression profiles 
have provided valuable clues for the identification of  key 
molecular pathways driving the neoplastic conversion of  
the liver[10-12]. Such studies have significantly contributed 
to the definition of  accurate prognostic genetic signa-
tures, and to the identification of  relevant therapeutic 
targets, some of  which are currently being validated in 
the clinical setting[13-15]. However, conventional microar-
ray approaches are not robust enough to detect the subtle 
differences in the transcriptome that arise through alter-
native splicing mechanisms, and therefore potentially rel-
evant alterations involved in the carcinogenic process can 
be missed[16,17]. Indeed, a large proportion of  the diversity 
within the transcriptome is generated by alternative splic-
ing, a mechanism through which multiple mRNAs and 
structurally different proteins can be produced from a 
single gene and that may affect more than 70% of  human 
genes[18,19]. The protein products generated by alternative 
splicing can have different or even antagonistic biological 
roles, and therefore their relative levels may impact signif-
icantly on cell function. Alterations in mRNA splicing are 
important cause of  disease, as illustrated by the fact that 
single-point mutations affecting splicing represent at least 
15% of  all disease-causing point mutations[20]. The rela-
tionship between alternative splicing and cancer has also 
been clearly established, cancer-specific splice variants 
and cancer-associated changes in the relative levels of  
spliced isoforms of  genes with an established role in car-
cinogenesis have been observed[21-25]. Moreover, in some 
cases the pro-tumorigenic effects of  these changes have 
been directly demonstrated, and the mechanisms leading 
to the appearance of  these tumor-associated alterations in 
normal mRNA splicing are now being elucidated[24,25]. To-
gether these findings attest to the importance of  dysregu-
lated pre-mRNA splicing in cancer. However, compared 
to other types of  tumors, less information is available on 
the disruption of  normal splicing in liver cancer and its 
biological significance. Here we discuss representative 
cases that illustrate the importance that perturbations in 
this process may have from the early stages of  hepatocar-
cinogenesis.
OVERVIEW OF THE BASIC MECHANISMS 
OF PRE-MRNA SPLICING AND ITS 
REGULATION
Most eukaryotic pre-mRNAs contain noncoding sequenc-
es (introns) that need to be removed to generate the cor-
rect concatenation of  exonic sequences[18,19]. Introns repre-
sent more than 90% of  the length of  pre-mRNAs, and the 
spliceosome, a complex nuclear machine, needs to accu-
rately identify specific nucleotide sequences at intron-exon 
boundaries to carry out intron excision and exon joining. 
The spliceosome is composed of  five types of  small nu-
clear ribonucleoproteins (snRNPs), plus a large number 
of  ancillary proteins. This complex is able to recognize a 
5’ donor splice site beginning with a GU dinucleotide, and 
a 3’ acceptor site ending with an AG dinucleotide at the 
boundaries of  introns, as well as the so-called branching 
sequence that precedes the 3’ acceptor site. The 5’ splice 
site is recognized by the U1 snRNP, while the branch-
ing sequence and the 3’ acceptor site are recognized and 
bound by the U2 snRNP and the auxiliary factor U2AF, 
respectively (Figure 1A)[21]. Subsequent interaction with 
the U4, U6 and U5 snRNPs leads to the formation of  the 
catalytically active complex that carries out the trans-ester-
ification reactions, resulting in the cleavage and religation 
of  the mRNA chain.
The accurate excision of  introns requires the recogni-
tion of  the above-mentioned consensus sequences that 
identify the splice sites[26]. Deviations from these consen-
sus sequences generate weak sites that have less affinity 
for their respective snRNPs, resulting in less efficient exon 
recognition and therefore allowing the alternative selec-
tion of  exons[21,24]. In these cases an additional class of  
sequence elements present both in introns and exons may 
come into play and modulate the selection of  splice sites 
by the spliceosome machinery. These sequences, known 
as splicing enhancers and silencers, are short conserved 
elements of  about 10 nucleotides that can enhance or 
repress exon recognition. The specific binding of  a wide 
range of  splicing regulatory proteins, such as SR proteins 
and heterogeneous nuclear ribonucleoproteins (hnRNP), 
to these elements in pre-mRNAs influences (positively or 
negatively) the placement of  the spliceosome on the ap-
propriate splice sites (Figure 1B). This mechanism allows 
the facultative use of  weak splice sites and mediates the 
generation of  alternatively spliced mRNAs[19,24]. Neverthe-
less, many if  not all exons contain exonic splicing enhanc-
ers that tend to be clustered around splice sites, and these 
elements are of  particular high density within constitutive 
exons. As discussed by Jensen et al[26], this suggests that 
enhancers are important for the control of  constitutive 
exon splicing, even in the presence of  consensus splice 
sites. Exonic splicing silencers also help to define exon 
boundaries, and strongly affect splicing when there are 
cryptic or multiple splice sites of  similar strength. These 
elements are thought to play a more prominent role in the 
control of  alternative splicing[26,27]. Figure 2 summarizes 
3092 July 7, 2010|Volume 16|Issue 25|WJG|www.wjgnet.com
the different alternative splicing events observed, these 
include: (1) exon skipping (cassette exons), in which the 
exon can be spliced from the transcript together with its 
flanking introns; (2) alternative 5’ and (3) 3’ splice site se-
lection, where two or more splice sites can be recognised 
in an exon; (4) intron retention, in which an intron can re-
main in the mature mRNA; (5) alternative polyadenylation 
signals, which allows the generation of  isoforms with 3’ 
untranslated regions (UTRs) of  different length; and (6) 
the alternative usage of  promoters, with the generation of  
isoforms with promoter associated exons[18,19].
SR proteins are highly conserved RNA-binding pro-
teins that facilitate splice site recognition and promote the 
inclusion of  exons in the mature mRNA. The SR protein 
family members mostly interact with exonic splicing en-
hancers (ESE), stabilising the interaction of  snRNPs and 
other factors at splice sites. Among other factors this fam-
ily includes the ASF/SF2, 9G8, SC35, SRp30c, SRp20, 
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Figure 2  Different modes of alternative splicing. After pre-mRNA processing a single gene can encode multiple mRNA isoforms that possess distinct coding 
and regulatory sequences. Alternative splicing isoforms can result from: 1: The skipping or inclusion of alternative exons; 2: The selection of alternative 5’; or 3: 3’ 
splice sites (SS); 4: The inclusion of introns; 5: The selection of different polyadenylation sites [AAA(n)]; and 6: The transcriptional initiation at an alternative promoter 
associated with the inclusion of specific exons. 
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Figure 1  Splicing consensus sequences and interactions with small nuclear ribonucleoproteins (snRNPs), SR proteins and heterogeneous nuclear 
ribonucleoproteins (hnRNPs). A: Arrangement of donor and acceptor sites in a eukaryotic gene and interaction with snRNPs during splicing. Core elements 
necessary for pre-mRNA splicing include the 5’ and 3’ splice sites and a branch point sequence and a polypyrimidine-rich tract located upstream of the 3’ splice site. 
The splicing factor U2AF (U2 auxiliary factor) consists of two subunits which bind to the 3’ splice site and the polypyrimidine tract. U2AF promotes the binding of U2 
snRNA in the U2 snRNP complex to the branch site. The U1 snRNP particle binds to the upstream and downstream 5’ splice sites through base pairing of the U1 
snRNA. The additional assembly of the snRNPs U4, U5 and U6 is required for the constitution of the spliceosome and the removal of introns; B: Interaction of splicing 
regulatory proteins with exonic and intronic target sequences. SR (Ser-Arg) proteins bind to exonic splicing enhancers (ESEs) to stimulate the binding of U2AF to a 
weak 3’ splice site, which here is interrupted by purines (R). They also stimulate the binding of the U1 snRNP to the downstream 5’ splice site. SR proteins antagonise 
the negative effect on splicing of hnRNPs bound to exonic splicing silencers (ESSs). In many cases, U-rich sequences situated immediately downstream of 5’ splice 
sites known as intronic splicing enhancers (ISEs) are bound by factors such as T cell-restricted intracellular antigen 1 (TIA1) to facilitate U1 binding.
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SRp40 and SRp46 proteins[27]. In contrast to the SR pro-
teins the hnRNPs, such as hnRNPA1 and hnRNP Ⅰ, have 
been mainly implicated in exon skipping. hnRNPA1 binds 
to exonic splicing silencers (ESS) and is able to prevent 
the binding of  SR proteins to their specific sites in the 
exonic region, while hnRNPI competes with the U2AF 
auxiliary factor for its binding sequence close to the 3’ 
splice site[24,28]. Variations in the expression levels of  these 
splicing factors are known to affect the selection of  splice 
sites, and therefore are thought to significantly influence 
the relative levels of  splice variants among different tis-
sues and also between normal and transformed cells[23,24]. 
Interestingly, accumulating evidence points also to the 
influence of  extracellular stimuli on the regulation of  al-
ternative splicing[28,29]. In this respect, the activity of  splic-
ing factors is known to be affected by their phosphoryla-
tion status[30]. For instance SR proteins can be extensively 
phosphorylated on Ser residues, and their phosphoryla-
tion status affects protein-protein and protein-RNA 
interactions[28,30]. Moreover, extracellular signals can also 
impinge on the subcellular localisation of  splicing factors, 
and consequently modulate their ability to interact with 
pre-mRNAs. This has been shown for different members 
of  the SR protein family[29], and also for the splicing fac-
tor Slu7[31]. Several kinases and phosphatases responsible 
for the post-translational modification of  splicing factors 
have been identified, and these include for instance the SR 
protein kinases (SRPKs), Clk/Sty, CDC-2 related protein 
kinase-7, and more recently, Akt and Fas-activated Ser/
Thr kinase (FASTK)[28,29,32,33]. Among the phosphatases 
able to dephosphorylate splicing factors of  the SR fam-
ily we can cite PP1 and PP2A[29]. Less is known regard-
ing the extracellular signalling pathways that control the 
activity of  splicing factors, however, recent experimental 
efforts are beginning to pay off  and relevant pathways 
are being delineated[29]. For example, insulin treatment has 
been shown to increase SRp40 phosphorylation and to 
stimulate protein kinase CβⅡ alternative splicing via Akt2 
activation[34]. Similarly, growth factors like the epidermal 
growth factor (EGF) have been demonstrated to modu-
late the splicing of  the surface antigen CD44 in HeLa 
cells through the activation of  Ras/mitogen-activated 
protein kinase (MAPK) cascade[35]. More recently, the ac-
tivation of  the EGF receptor (EGFR) was also shown to 
regulate the alternative splicing of  the tumor suppressor 
genes Krüppel-like zinc finger transcription factor 6 (KLF6) and 
p73 in HCC cells. Although this will be discussed later in 
more detail, alternative splicing of  KLF6 pre-mRNA trig-
gered by EGFR stimulation involved the Ras/phosphati-
dylinositol 3-kinase (PI3K)/Akt cascade, while that of  p73 
specifically depended on c-Jun N-terminal kinase (JNK) 
activation[36,37]. Complex interactions between intracellular 
signalling pathways in the control of  alternative splicing 
are also emerging. Such as the case of  the antagonistic ef-
fect of  JNK signalling on PI3K-mediated splicing regula-
tion of  the fibronectin gene in response to extracellular 
stimuli[38]. Taken together, these observations underscore 
the dynamic nature of  alternative splicing, and also the 
high sensitivity to environmental signals displayed by this 
fundamental mechanism of  gene expression regulation.
MECHANISMS AND SIGNIFICANCE OF 
ALTERATIONS IN PRE-MRNA SPLICING 
IN HEPATOCARCINOGENESIS
As previously mentioned, alterations in pre-mRNA splic-
ing patterns, including changes in the normal tissular pat-
terns of  alternative splicing and the appearance of  tumor-
specific aberrantly spliced mRNAs, are increasingly being 
reported and implicated in cancer[39,40]. The mechanisms 
responsible for these alterations observed in cancer cells 
are still not well known. Nevertheless, some of  these 
mechanisms are currently being elucidated and include: 
(1) mutations that create or disrupt splice sites or splic-
ing enhancers or silencers[21]; (2) the abnormal expression 
of  splicing factors[22,23,41,42]; and (3) the activation of  cell 
signalling pathways that affect the activity of  the splicing 
machinery[21,29]. In spite of  recent advancements a major 
challenge in the field is still to discriminate whether these 
changes in alternative splicing can be the cause or are the 
consequence of  human diseases. This is especially difficult 
in neoplastic diseases like HCC, if  we take into account 
the multiple and heterogeneous genetic alterations that 
occur along the multi-step process of  hepatocarcinogen-
esis, and the profound effects that the tumor microenvi-
ronment may have on transformed cells. Nevertheless, in 
some cases direct evidence has been provided on the on-
cogenic potential of  liver cancer-associated splice variants 
and on the mechanisms involved in their generation. In-
terestingly, some cancer-associated isoforms have already 
been detected at pre-neoplastic stages, suggesting their 
potential early contribution to liver malignisation. Below 
we discuss some examples that are summarised in Table 1. 
One interesting case of  dysregulated alternative splic-
ing occurring early during human hepatocarcinogenesis 
was reported by Saito et al[43]. These authors described the 
overexpression of  a splice variant of  DNA methyltrans-
ferase 3b (DNMT3b), namely DNMT3b4, in liver tissues 
showing chronic hepatitis and cirrhosis, as well as in HCC 
tissue samples. In contrast to DNMT3b3, the major vari-
ant in normal liver tissues, the DNMT3b4 splice variant 
lacks the conserved methyltransferase motifs Ⅸ and Ⅹ 
in exon 21, and probably also lacks this enzymatic activ-
ity. An elevation of  the ratio of  DNMT3b4 to DNMT3b3 
mRNA was significantly correlated with the degree of  
DNA hypomethylation on pericentromeric satellite regions 
in precancerous conditions and HCC[43]. Hypomethylation 
of  pericentromeric satellite regions may induce chromo-
somal instability, and is considered an early event during 
hepatocarcinogenesis. The authors hypothesised that the 
protein product of  DNMT3b4 transcript might compete 
with the active variant DNMT3b3, behaving as a domi-
nant negative isoform. They confirmed this possibility 
by transfecting HEK293 epithelial cells, which express 
the DNMT3b3 active variant, with a DNMT3b4 expres-
3094 July 7, 2010|Volume 16|Issue 25|WJG|www.wjgnet.com
Berasain C et al . Alternative splicing and liver cancer
sion vector and observed satellite DNA demethylation[43]. 
Furthermore, subsequent observations demonstrated that 
DNMT3b4 transfection resulted in enhanced growth rate 
and increased expression of  transformation-related genes, 
even before chromosomal alterations appeared, underscor-
ing the profound biological consequences of  this altered 
splicing event[44]. 
Other examples of  aberrantly-spliced genes detected 
in the preneoplastic cirrhotic liver include the serine/thre-
onine kinase aurora kinase B (AURKB), and the E3 ubiq-
uitin ligase and p53-antagonistic protein MDM2. AURKB, 
which is expressed in normal liver tissue, had been shown 
to be overexpressed in HCC correlating with tumor re-
currence and a poor prognosis[45]. It was subsequently 
observed that over 60% of  metastatic liver cancer tissues 
expressed the AURKB splice variant 2 (AURKB Sv2), 
which was also present in about 16% of  the cirrhotic tis-
sues tested regardless of  their aetiology, but was absent in 
the normal liver parenchyma[46]. Interestingly, AURKB Sv2 
variant-positive HCC samples were mostly obtained from 
younger patients, and correlated with a poor outcome and 
short disease-free period[46]. From a mechanistic point of  
view the contribution of  AURKB Sv2 to hepatocarcino-
genesis is not known. This splice variant lacks parts of  the 
kinase domain, and it could compete with the full length 
AURKB in a dominant negative manner, but experimen-
tal data on this aspect are not available yet. Regarding 
MDM2, two splice variants with tumorigenic potential, 
which are absent in the normal liver tissue, were found in 
alcoholic and autoimmune liver cirrhosis. However, for 
still unknown reasons these variants were not detected in 
hepatitis C virus (HCV)-infected cirrhotic samples[47].
As previously mentioned, the experimental demonstra-
tion of  the pro-oncogenic effects of  the splice variants 
found in transformed tissues is important to establish a 
cause and effect relationship. This is commonly done by 
expressing the splice variant under evaluation in cultured 
cell lines, as presented above for DNMT3b4, and more 
recently also by the generation of  transgenic animals with 
targeted expression of  the spliceoform in question. Al-
though these approaches can be limited by the generally 
unphysiological expression levels obtained, relevant mech-
anistic information may be drawn from these studies. For 
instance, Yam et al[48] found that the Tensin 2 splice variant 
3 (TENSIN 2sv3) was overexpressed in 46% of  HCC tis-
sues and most HCC cell lines examined, and that the ex-
pression of  this variant correlated with a more aggressive 
tumor phenotype and other pathological features of  poor 
prognosis. Tensins constitute a new family of  focal adhe-
sion proteins that link the extracellular matrix to the actin 
cytoskeleton and to intracellular signalling pathways. To 
directly assess the consequences of  TENSIN 2sv3 overex-
pression, the authors generated stable clones in a HCC cell 
line with low TENSIN 2sv3 expression. These clones dis-
played increased growth, invasive properties, and tumori-
genicity in an orthotopic model of  HCC[48]. Together these 
findings identified a novel determinant in the metastatic 
behaviour of  HCC which is generated by alternative splic-
ing. Another cytoskeletal protein recently shown to be ab-
errantly spliced in HCC is the product of  the Hugl-1 gene, 
a tumor suppressor mainly expressed in the cytoplasm and 
involved in the regulation of  cell polarity. Lu et al[49] found 
that 32.5% of  HCCs displayed aberrant spliced variants of  
this gene that lacked a conserved repeat motif  involved in 
protein-protein interactions. The presence of  these Hugl-1 
variants correlated with poor differentiation and large tu-
mor size, and their overexpression in HCC cells resulted in 
enhanced invasion and tumorigenicity when injected into 
nude mice. Similar findings were recently reported for the 
mitotic arrest deficient 1 (MAD1) gene. Sze et al[50] identified a 
novel MAD1 splice variant in human HCC samples which 
they named MAD1β , while the original wild-type isoform 
was renamed MAD1α . MAD1α is a key protein in the 
mitotic checkpoint complex that monitors the status of  
kinetochore-microtubule attachment and the formation of  
the connections to the mitotic spindle. Defective mitotic 
checkpoint leads to DNA aneuploidy and chromosomal 
instability, which are features of  HCCs[51]. MAD1β was 
overexpressed in 24% of  the HCC tissue samples com-
pared to the surrounding parenchyma, and interestingly 
more than 50% of  the cases expressed MAD1β both in 
the tumoral and nontumoral tissue. MAD1β lacks the 
exon 4 of  MAD1α, and is localised to the cytoplasm in-
stead of  the cell nucleus. MAD1β overexpression also af-
fected the subcellular location and protein levels of  other 
key components of  the mitotic checkpoint such as MAD2. 
Functional studies overexpressing MAD1β in HCC cell 
lines demonstrated that the presence of  this splice vari-
ant resulted in severe chromosome aberrations, thus 
demonstrating that MAD1β induces mitotic checkpoint 
incompetence[50]. Finally, there are also examples in which 
the specific targeting and downregulation of  an aberrant 
splice variant found in HCC cells and tissues results in 
reduced tumorigenesis. This is the case of  the “specific 
Splicing Variant involved in Hepatocarcinogenesis” (SVH) 
gene, an armadillo repeat domain containing gene of  still 
unknown biological function that can produce four splice 
variants (SVH-A, -B, -C and -D). Only the splice variant 
SVH-B was upregulated in HCC tissues and hepatoma 
cell lines, and only the overexpression of  this variant in 
non-transformed liver cell lines resulted in accelerated cell 
growth and tumorigenicity in nude mice[52]. Interestingly, 
the specific inhibition of  SVH-B with antisense oligode-
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Table 1  Examples of genes with altered splicing in liver 
carcinogenesis
Gene Function Selected ref.
DNMT3b4 DNA methyltransferase [43,44]
MDM2 E3 ubiquitin ligase [47]
Aurora kinase B Sv2 Serine/Threonine kinase [45,46]
Hugl-1 Tumor suppressor [49]
Tensin 2var3 Focal adhesion [48]
Cadherin 17 Cell surface adhesion [55]
MAD1 (β) Spindle-assembly checkpoint [50]
KLF6 Tumor suppressor [36]
SVH Unknown [52]
p73 Tumor suppressor [37,72]
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oxynucleotides reduced HCC cell growth and survival[52]. 
This observation also suggests the possibility of  specifical-
ly targeting aberrantly spliced mRNAs to quell liver cancer, 
as will be discussed later.
The observations described above illustrate the onco-
genic potential of  aberrantly spliced isoforms in HCC tis-
sues. However, for all these cases no information is so far 
available regarding the molecular events involved in their 
generation[43,48-50,52]. In fact, the mechanisms that lead to the 
appearance of  aberrantly-spliced genes in hepatocarcino-
genesis have been so far elucidated for a limited number 
of  genes. Among them we find Cadherin 17 (CDH17), also 
known as liver-intestine cadherin (LI-Cadherin), a non-
classic member of  the cadherin family of  cell-cell adhe-
sion proteins overexpressed in about 90% of  HCCs[53,54]. 
CDH17 expression was shown to confer tumorigenic po-
tential to premalignant liver progenitor cells[53]. Interesting-
ly, it was later found that 50% of  HCC samples, and 30% 
of  peritumoral tissues, also expressed a CDH17 splice 
variant lacking exon 7[55]. The expression of  this splice vari-
ant was strongly associated with decreased overall survival 
of  the patients[55]. While the reason why overexpression 
of  this splice variant may have a pathogenic role remains 
speculative, the mechanisms behind its generation have 
been characterised. Wang et al[55] detected a base change at 
position 651 in exon 6, and another single nucleotide poly-
morphism (SNP) in a putative branch point at intron 6 po-
sition 35 (IVS6+35) was also found. The mutation at posi-
tion 651 in exon 6 could affect exon 7 inclusion by gener-
ating an ESS, or by disrupting an ESE located in exon 6[21]. 
GG and AG polymorphisms were identified in 73% of  the 
patients at IVS6+35, and in the same patients TT and CT 
polymorphisms were also observed at 651 (exon 6), in the 
control group normal livers showed the wild-type pheno-
type 651 CC, IVS6+35 AA. The functional role of  these 
two SNPs was confirmed in a minigene assay, in which the 
presence of  651 T and IVS6+35 G SNPs resulted in exon 
7 skipping[55]. It was later observed that the 651 T IVS+35 
G haplotype, specially 651 TT and IVS6+35 GG homo-
zygotes, seemed to be strongly associated with HCC, and 
therefore could be considered as a genetic susceptibility 
factor for HCC development in a Chinese population[56]. 
While point mutations in splice or regulatory sites are 
perhaps the most common alterations leading to aberrant 
splicing in cancer, the role of  signalling pathways is gain-
ing recognition. This is very well illustrated by the study 
of  fibronectin alternative splicing regulation. Fibronectin 
is a glycoprotein found in blood, body fluids and tis-
sues that plays a key role in cell adhesion and migration. 
Fibronectin has a domain structure consisting of  three 
internally homologous repeats, termed type Ⅰ, Ⅱ and Ⅲ 
domains. There are two type Ⅲ domains that can be al-
ternatively spliced, and incorporated or not in the mature 
transcript, the extra domains A and B, denominated EDA 
and EDB[57]. In addition, the so-called type Ⅲ connecting 
segment (ⅢCS) can also be alternatively spliced, generat-
ing in total up to 20 fibronectin isoforms in humans[57]. 
Fibronectin is biologically classified in two forms, namely 
plasma and cellular fibronectin, and only cellular fibro-
nectin contains the EDA and EDB sequences. Plasma 
fibronectin is secreted by the hepatocytes, but these cells, 
as other normal adult cells, express limited amounts of  
EDA-containing fibronectin, which is expressed by foetal 
hepatocytes[57]. Several functions have been described for 
the EDA domain, including cell adhesion, wound heal-
ing, matrix assembly, matrix metalloproteinase expression, 
cell differentiation and tissue injury and inflammation[57]. 
Alternative splicing of  the EDA exon is controlled by a 
bipartite element comprising an ESE and an ESS[29,57]. Sre-
brow and co-workers[38,58,59] have characterised the effect 
of  extracellular matrix components and growth factors 
like EGF, hepatocyte growth factor and fibroblast growth 
factors, on fibronectin splicing. These authors observed 
that extracellular matrix components such as laminin and 
collagen Ⅳ downregulated EDA inclusion, while growth 
factors promoted the inclusion of  EDA in fibronectin 
mRNA[38,59]. The signalling pathways connecting the cell 
surface with the nuclear splicing machinery controlling 
fibronectin splicing were also investigated. Exposure to a 
laminin-rich basement membrane resulted in JNK activa-
tion and sustained extracellular signal-regulated kinase 
(ERK) dephosphorylation, and these events were mecha-
nistically linked to the described downregulation of  EDA 
inclusion[38]. On the other hand, growth factor-activated 
Ras-PI3K-mediated signalling was shown to alter the phos-
phorylation levels of  the SR proteins SF2/ASF and 9G8, 
and direct evidence was also provided on the importance 
of  these events in mitogen-stimulated EDA inclusion[32,38]. 
All the mechanistic observations on the modulation 
of  fibronectin splicing described above were carried out in 
mammary epithelial cells, however, they can be highly rele-
vant to the alterations of  fibronectin splicing found in liver 
disease. Indeed, EDA and EDB containing variants have 
been detected in the rodent liver during acute and chronic 
injury, and during liver regeneration after partial hepa-
tectomy[60-63]. In models of  liver injury, EDA-containing 
fibronectin was mainly produced by sinusoidal endothelial 
cells, while extracellular matrix-producing cells expressed 
EDB fibronectin[60,63]. In contrast, in human chronic hepa-
titis and in liver fibrosis EDA-containing fibronectin was 
detected not only in non-parenchymal cells, but also in he-
patocytes[63,64]. Moreover, both EDA- and EDB-containing 
fibronectin variants were detected in human HCC tissues, 
and were localised to hepatoma cells[62,65]. The molecular 
mechanisms involved in fibronectin alternative splicing 
in liver injury and transformation are currently unknown. 
However, the pro-inflammatory milieu characteristic of  
chronic liver injury and HCC activates the same intracellu-
lar pathways that promote fibronectin splicing in mamma-
ry epithelial cells. Therefore, it is likely that cytokines and 
growth factors upregulated during hepatocarcinogenesis 
promote the alternative splicing of  fibronectin in the liver. 
In support of  this is the positive effect of  transforming 
growth factor-β (TGFβ) on EDA inclusion observed in 
isolated mouse liver endothelial cells, or that of  TGF and 
EGF found in human HCC cells in culture[58,59,62]. The ex-
pression of  EDA-containing fibronectin during liver injury 
has been shown to contribute to the activation of  ECM-
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producing cells[60]. This effect, together with its ability to 
stimulate cell cycle progression and cellular migration ob-
served in other cell types[57], suggests its likely involvement 
in the neoplastic conversion of  the liver. 
Together with fibronectin, other relevant examples of  
genes for which extracellular signals are known to affect 
their normal alternative splicing are the tumor suppressor 
genes KLF6 and p73. As previously mentioned KLF6 is a 
ubiquitously expressed Krüppel-like zinc finger transcrip-
tion factor, and tumor suppressor gene that is functionally 
inactivated in a number of  cancers including HCC[66]. The 
KLF6 pre-mRNA can give rise to three alternative splice 
variants, and at least one of  them acts as a dominant-
negative protein that antagonises the full length KLF6. 
This variant, named KLF6 SV1, lacks the three zinc finger 
DNA binding domains but retains the activation domain 
that mediates protein-protein interactions essential for the 
biological activity of  this family of  transcription factors. 
KLF6 SV1 is overexpressed in several human cancers, 
correlating with poorer outcome and reduced survival[67]. 
Increased KLF6 alternative splicing, expressed as the ratio 
of  KLF6 SV1 to full length KLF6, was observed in 76% 
of  the HCC samples examined[36]. While full length KLF6 
overexpression in HCC cells inhibited growth and pro-
moted cell differentiation[68], the overexpression of  KLF6 
SV1 partially restored the decreased cell proliferation in-
duced by inhibition of  the Ras pathway[36]. Mechanistically, 
the first cause that was identified for the generation of  
KLF6 SV1 in cancer cells was the presence of  a SNP in 
intron 1 of  the KLF6 gene. This SNP abrogates a binding 
site for the splicing factor ASF/SF2 and generates a bind-
ing site for the SR protein SRp40, provoking the use of  
two cryptic splice sites in exon 2[66]. The presence of  this 
SNP in association with HCC development has not been 
tested so far. However, it was known that KLF6 could 
still be alternatively spliced into KLF6 SV1 in normal and 
cancerous tissues without this SNP[66]. One relevant mech-
anism for the generation of  KLF6 SV1 in HCC cells was 
recently outlined by Yea et al[36]. It involved the oncogenic 
activation of  the Ras/PI3K/Akt pathway and the splice 
regulatory protein ASF/SF2. Interestingly, upstream of  
Ras the authors identified the EGFR tyrosine kinase ac-
tivity as a signal that could trigger KLF6 SV1 generation. 
These findings may be of  special relevance for the biology 
of  HCC, they link a signalling pathway hyperactive in liver 
cancer[69] to the functional inactivation of  a tumor sup-
pressor gene through dysregulated alternative splicing. 
p73 is another tumor suppressor gene which is fre-
quently altered in different cancers, including HCC[70]. This 
gene is structurally related to p53, sharing common tran-
scriptional targets that promote cell cycle arrest, apoptosis 
and limit anchorage-independent cell growth[70]. However, 
at variance with p53, no inactivating mutations have been 
described for p73 in cancer cells. Inhibition of  p73 tumor 
suppressive activity derives from the coexpression of  
N-terminally truncated isoforms. Two of  these isoforms 
are known as ΔEx2p73 and ΔEx2/3p73, and are splice 
variants of  the full length p73 pre-mRNA that lack the 
transactivation domain, but retain the DNA binding do-
main and a C-terminal oligomerisation domain. ΔEx2p73 
and ΔEx2/3p73 behave as dominant negative inhibitors of  
both p53 and p73, and are not expressed in normal tissues, 
but are frequently up-regulated in HCC[37,71-73]. Forced ex-
pression of  these variants induces malignant transforma-
tion in fibroblasts and chemotherapy resistance in cancer 
cells[74,75]. Moreover, transgenic mice overexpressing hu-
man ΔEx2/3p73 in hepatocytes spontaneously developed 
HCC, attesting to the in vivo oncogenicity of  aberrantly 
spliced p73 variants for liver cells[76]. The mechanisms reg-
ulating the generation of  protumorigenic p73 variants are 
not known, however, a recent study by Castillo et al[37] iden-
tified a signalling pathway that promoted the generation of  
ΔEx2p73 in liver cells. It was observed that the stimula-
tion of  the EGFR by its ligand amphiregulin (AR) in an 
autocrine manner triggered the splicing of  p73 into its 
ΔEx2p73 variant[37]. AR expression is undetectable in the 
healthy liver, but it is upregulated during injury and in-
flammation, contributing to tissue repair but also to the 
progression of  liver disease[77-79]. Overexpression of  AR 
is detected in liver tumors, and significantly participates 
in the maintenance of  the neoplastic phenotype of  HCC 
cells[79]. Interestingly, the expression of  AR significantly 
correlated with the presence of  ΔEx2p73 transcripts not 
only in tumor tissues, but also in cirrhotic livers. Further-
more, this correlation was also observed in the non-neo-
plastic normal parenchymal tissue of  livers that developed 
HCC in the absence of  any risk factor for this neoplasia[37]. 
These findings suggest that AR-mediated dysregulation of  
p73 pre-mRNA splicing can be an early event during he-
patocarcinogenesis, including those cases in which cancer 
develops in a tissue not chronically injured. Mechanisti-
cally it was demonstrated that downstream of  the EGFR 
the activation of  JNK1 resulted in the downregulation of  
the splicing factor Slu7 in HCC cells[37]. Slu7 is involved in 
the correct selection of  the 3’ splice site during the sec-
ond step of  splicing, and it has been demonstrated that 
Slu7 knockdown results in exon skipping of  endogenous 
genes[80]. Inhibition of  Slu7 expression by AR/EGFR/
JNK1 signalling involved the activation of  the transcrip-
tion factor Elk-1, a previously recognised repressor of  Slu7 
transcription[80]. Of  importance, the expression of  Slu7 
was also found to be significantly decreased in chronic 
liver disease and HCC. Together, these observations iden-
tify a cancer-related extracellularly triggered signalling 
pathway that culminates in the transcriptional knockdown 
of  a splicing factor, and the consequent generation of  an 
oncogenic splice variant. 
As mentioned before, abnormally expressed splicing 
factors can induce the production of  mRNA isoforms 
nonexistent or present in low amounts in normal cells. 
Increasing evidence points to the significant contribution 
of  this phenomenon to malignant progression, as recently 
demonstrated by the oncogenic consequences of  SF2/
ASF overexpression[41,81], or the contribution to the cancer-
ous phenotype of  hnRNP proteins upregulation[42]. How-
ever, a decrease in the expression of  splice factors is less 
frequently observed in cancer cells, although some cases 
have been reported[23]. For instance reduced expression of  
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U2AF was found in pancreatic cancer[82], and siRNA-me-
diated inhibition of  its expression in HeLa cells increased 
the level of  the oncogenic CDC25B phosphatase[83]. In 
view of  this, the downregulation of  Slu7 gene expression 
in the cirrhotic liver may have mechanistic implications for 
the progression towards HCC.
POTENTIAL THERAPEUTIC 
INTERVENTIONS TARGETING SPLICING 
DEFECTS
The appreciation that dysregulated splicing may influence 
the development of  human disease makes this process a 
potential therapeutic target. Different strategies are cur-
rently being explored to correct or inhibit pathological 
splicing events. They may be grouped in two major cat-
egories: molecules that can change alternative splicing and 
antisense strategies[39,84-86]. 
High throughput screens and individual studies on 
specific molecules have identified a number of  com-
pounds that can change splice site selection. For instance 
two different natural products with broad anticancer 
activity, pladienolide and spliceostatin A, have been re-
cently reported to bind and interfere with the essential 
splicing protein SF3b, a core component of  the U2 sn-
RNP, inhibiting the splicing of  a number of  transcripts 
resulting in growth inhibition[87,88]. 
Targeting the expression and the post-translational 
modifications of  splice modulators have also been at-
tempted with promising results. As mentioned before, 
there are several kinases that phosphorylate the SR pro-
teins in their arginine/serine domains (RS), affecting their 
intracellular localisation and their interaction with other 
splice factors and the pre-mRNAs. These kinases include 
topoisomerase Ⅰ (Topo Ⅰ) and members of  the Clk/Sty 
and SRPK families[84,85]. Several antineoplastic compounds 
that target Topo Ⅰ, such as diospyrin and indole deriva-
tives like NB-506, can modify splice site selection. NB-506 
inhibited the phosphorylation of  SF2/ASF and altered the 
splicing pattern of  several target genes including the apop-
tosis regulator Bcl-X in tumor cells[89]. The Clk1 kinase 
inhibitor TG003 also interferes with SF2/ASF-dependent 
splicing and can suppress alternative splicing in reporter 
genes[90]. The specific targeting of  SRPK1 may be of  
special relevance, given its prominent role in cancer cells. 
Downregulation of  SRPK1 expression by siRNA was 
reported to inhibit cancer cell proliferation and increase 
the sensitivity to chemotherapeutics[91], therefore the inhi-
bition of  this kinase may be an effective pharmacological 
strategy. Another approach to modify the activity of  splice 
modulators is to target protein phosphatases (PPs). PP1 
can bind directly to a conserved motif  in the RNA-recog-
nition region of  at least nine splicing-regulatory proteins[84]. 
Modulation of  PP1 activity shows a strong influence on 
alternative splicing, as illustrated by the lipid ceramide 
which activates PP1 and promotes the alternative splicing 
of  the apoptosis regulator Bcl-X into its pro-apoptotic 
variant Bcl-Xs[92]. Activation of  PP1 expression and up-
regulation of  Bcl-Xs levels have also been demonstrated to 
occur in response to S-adenosylmethionine (AdoMet) and 
5’-methylthioadenosine (MTA) treatment in HCC cells[93]. 
Interestingly, these two naturally occurring compounds 
show antitumoral effects in HCC and can induce growth 
inhibition and apoptosis in liver cancer cells, while normal 
hepatocytes are spared from this effect[94,95]. The reasons 
why AdoMet and MTA promote PP1 expression and Bcl-
Xs upregulation only in HCC cells are still unknown, but 
this fact represents an advantage over other experimental 
approaches in which splicing can be altered both in normal 
and cancerous cells. 
The selective modulation of  splicing reactions is a big 
challenge, and the specific target of  one splicing event is 
difficult to achieve with the above-mentioned compounds. 
This can be addressed with antisense oligonucleotides that 
can complementarily bind to a target site in pre-mRNAs 
and regulate the splicing process. Antisense oligonucle-
otides can block cryptic splicing sites created by a muta-
tion, and redirect splicing back to the correct splice site. 
They can be used to induce exon skipping, and can also be 
targeted to regulatory sequence elements within exons and 
introns, like ESEs and ESSs[86]. These antisense oligonucle-
otides must be stable in biological fluids, and also need to 
be efficiently delivered inside target cells. To achieve the 
desired stability, chemical modifications are introduced 
that prevent degradation. To increase cellular delivery, 
formulations coupling oligonucleotides to arginine-rich 
cell penetrating peptides have been devised[39]. Moreover, 
intracellular delivery of  antisense oligonucleotides to cor-
rect splicing defects has also been attained using adenoviral 
vectors[96]. The new generation antisense oligonucleotides 
include: phosphoroamidate morpholino oligomers, pep-
tide nucleic acids (PNA), and locked nucleic acids (LNA)[86]. 
Morpholino oligonucleotides have been used to inhibit 
splicing silencers and to activate otherwise repressed ex-
ons. This has been shown for instance for the α exon of  
fibroblast growth factor receptor 1 (FGFR1), which is 
excluded in glioblastoma cells[97]. PNAs are oligonucleotide 
analogs in which the nucleobases are bound to a polyam-
ide backbone that is highly stable in vivo[98]. They have been 
tested in cultured cells and in vivo with promising results, 
inducing the splicing of  Bcl-X and promoting apoptosis in 
cancer cells[99]. LNA antisense oligonucleotides contain 
a methylene bridge that connects the 2’-oxygen of  the 
ribose with the 4’-carbon. This modification increases the 
serum stability of  oligonucleotides, prevents their degrada-
tion by RnaseH, and imparts high specificity toward their 
target sequences[100]. LNAs have been successfully used to 
modulate the splicing of  tumor necrosis factor receptor 2 
(TNFR2) in the liver, switching the endogenous expression 
of  the membrane bound functional form of  TNFR2 to a 
soluble secreted form lacking exon 7 (Δ7TNFR2). The 
secreted form acted as a decoy receptor for TNF-α, and 
mice were protected from liver damage in a model of  acute 
inflammation and injury[101]. LNAs have also been used to 
target and promote the degradation of  specific oncogenic 
splice forms. This has been shown recently by Emmrich 
and co-workers[102], who designed LNA antisense oligo-
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nucleotides directed against the ΔEx2p73 and ΔEx2/3p73 
oncogenic isoforms of  the tumor suppressor p73, which 
as previously described are upregulated in HCC. Specificity 
was obtained by targeting the splice junction of  each exon 
deletion variant. This strategy reduced tumorigenic p73 
transcripts, without affecting wild-type p73, and inhibited 
malignant melanoma growth. Additional examples illus-
trating the potential of  antisense oligonucleotide-based 
strategies to correct splicing defects have been recently 
reviewed in detail by Khoo and Krainer[103]. Among other 
cases, these authors describe how the splicing of  liver apo-
lipoprotein B 100 (APOB100), a key player in the devel-
opment of  atherosclerosis, can be engineered without af-
fecting the expression of  the intestinal isoform APOB48, 
involved in fat absorption from the gut. Specific targeting 
of  APOB100 pre-mRNA with antisense oligonucleotides 
induced the skipping of  exon 27, leading to the generation 
of  a shorter variant that has been associated with reduced 
cholesterol and LDL levels[103].
Also within these targeted strategies, a recent report by 
Alló and co-workers demonstrated that small interfering 
RNAs (siRNAs) targeting gene sequences surrounding 
an alternative exon (the flanking introns) can modulate its 
alternative splicing, resulting in exon inclusion[104]. It was 
found that upon siRNA transfection there was an increase 
in the levels of  facultative heterochromatin in the vicinity 
of  the siRNA target sites. The authors proposed that the 
condensed chromatin structure slows down Pol Ⅱ elon-
gation and facilitates the inclusion process. Regardless of  
the mechanistic details underlying this phenomenon, these 
findings open the door to the application of  siRNA tech-
nology to correct splicing defects.
Although further studies are needed, together these ob-
servations demonstrate that targeting the splicing machin-
ery is feasible and can also be achieved in vivo. Moreover, 
the application of  antisense-based therapeutic strategies 
may be especially effective to treat liver diseases, as sug-
gested by the preferential accumulation of  antisense oligo-
nucleotides in this organ when administered to mice[105]. 
HCC is a molecularly complex type of  tumor, how-
ever, the identification of  key splicing defects that may be 
corrected or interfered with targeted molecules as outlined 
above could help to develop new therapeutic strategies. 
These strategies may be used in combination with other 
targeted therapies, or with conventional chemotherapeutic 
approaches.
CONCLUSION
The detection of  splicing aberrations from early stages of  
hepatocarcinogenesis together with the validation of  their 
functional significance, suggests the likely implication of  
splicing defects in the oncogenic transformation of  the 
liver. The realisation of  this is just a start point for future 
research aimed at the development of  effective therapeu-
tic interventions in a deadly disease like HCC. There are 
different fronts in which action is needed. For instance, a 
thorough knowledge of  the splicing alterations in pre-neo-
plastic and transformed liver tissue is still lacking. The use 
of  improved splice-sensitive microarray platforms, and the 
implementation of  new technologies like deep sequencing 
of  transcriptome (RNA-seq), that allows both known tran-
script quantification and novel transcript discovery, are like-
ly to yield valuable information on all splicing events[106,107]. 
These approaches will allow the identification of  new splic-
ing defects with potential pathological significance, and the 
generation of  splicing signatures that may have prognostic 
value. The characterisation of  functional splice regulatory 
elements in the genome that can be targeted by RNA bind-
ing proteins is also a challenge. New methods combining 
immunoprecipitation of  RNA-protein complexes with 
high-throughput sequencing of  reverse transcribed tags are 
currently being devised[19,106]. From the therapeutic perspec-
tive, it is possible that alterations in pre-mRNA splicing 
resulting from hyperactive intracellular signalling pathways 
could be reversed in part by the emerging targeted therapies 
that block these pathways[6,15,36,37]. However, when aberrant 
splicing is the consequence of  genetic mutations that affect 
splicing reactions, and are not due only to the dysregulation 
of  signalling pathways that impinge on pre-mRNA splic-
ing, different approaches must be used. In these cases that 
involve structural changes due to mutations, the inhibition 
of  hyperactive signalling pathways may not be effective, 
and the antisense oligonucleotides described above can be 
applied. Nevertheless, some aspects such as their potential 
off-target effects and their efficient delivery to the target 
tissues still need to be further elaborated[86]. In summary, 
the integration of  pre-mRNA processing alterations in the 
molecular portrait of  liver cancer will surely contribute to 
the understanding of  the disease and the development of  
new effective therapies.
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